GlassScriptPhysician profile
David W Puett
NPI 1821096264
$862.96
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $133 · 2021: $266 · 2022: $31.82.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $177.40 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.00 | 2019-2021 | |
| Amgen INC. | $82.38 | 2019-2021 | |
| Janssen Biotech, INC. | $69.45 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $61.95 | 2019-2020 | |
| Ucb, INC. | $57.19 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $53.53 | 2019-2021 | |
| Genentech USA, INC. | $52.10 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $47.29 | 2019-2020 | |
| Horizon Therapeutics Plc | $40.13 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $28.81 | 2021-2022 | |
| Pfizer INC. | $25.93 | 2019 | |
| Glaxosmithkline, LLC. | $22.30 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.01 | 2021 | |
| Aurinia Pharma U.S., INC. | $17.22 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $16.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Puett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.